Our Mission

The mission of PPMI is to identify one or more biomarkers of Parkinson’s disease progression. The discovery of a biomarker is a critical step in the development of new and better treatments for PD. This study is being sponsored by The Michael J. Fox Foundation for Parkinson's Research.

PPMI Enrollment Status

Prodromal Participants
Enrollment Goal: 100

Genetic Cohort Participants
Enrollmen Goal: 600

Genetic Registry Participants
Enrollment Goal: ~600

De Novo PD Participants
Enrollment Goal: 400

Control Participants
Enrollment Goal: 200

Subjects with SWEDD
Enrollment: 64

Last Update: March 2, 2015


More about study cohorts >


Welcome to the Parkinson’s Progression Markers Initiative (PPMI), a landmark observational clinical study to comprehensively evaluate cohorts of significant interest using advanced imaging, biologic sampling and clinical and behavioral assessments to identify biomarkers of Parkinson’s disease progression.

PPMI is taking place at clinical sites in the United States, Europe, Israel, and Australia. Data and samples acquired from study participants will enable the development of a comprehensive Parkinson’s database and biorepository, which is currently available to the scientific community to conduct field-changing research.

PPMI is made possible by the concerted efforts of a number of collaborators. This study is sponsored by The Michael J. Fox Foundation for Parkinson’s Research.

Learn more about Who We Are.


2015 PPMI Study Update Call Series

Enrolled participants can take part in the PPMI Study Update Call Series. Calls take place on a quarterly basis and feature presentations and Q&A with leading researchers and study team members. View the 2015 call schedule.

New Feature: Archive of Study Protocols

An archive of study protocols and schedules of activities is now available. The archive provides a clear history of the study’s progress and serves as a resource for researchers using the PPMI database and biospecimens.

2015 Sample Request Rolling Application Deadlines

Qualified researchers can request access to PPMI biospecimens through the rolling application process. Mark your calendars with the 2015 schedule to ensure timely submission and review.

Genetics Participant Study Update Call

Andrew Singleton, PhD, principal investigator of the PPMI Genetics Core at the National Institute on Aging/NIH was the latest guest speaker in the PPMI Study Update Call series for enrolled participants. You can now listen to this call about PPMI, genetics, and PD on the For Enrolled Participants page.

PPMI Biosamples Webinar Posted

PPMI’s principal investigator, Ken Marek, MD, and The Michael J. Fox Foundation’s Mark Frasier, PhD held the PPMI Progress Update: Available Data and Biosamples webinar, covering an overview of PPMI, some initial findings, and the process for accessing the PPMI clinical data, imaging data, and biospecimens. A recording of the webinar is now available.

Learn More